The top priority for cardiotoxicity in cancer patients: full attention, full monitoring, and early diagnosis of OCC 2021

*Only for medical professionals to read and refer to the latest points of the OCC conference! The 15th Oriental Cardiology Conference (OCC 2021) will be held in Shanghai on May 27-30, 2021 through a combination of online and offline.
The big names gather to talk about the frontiers and hotspots of the cardiovascular field.

In chemotherapy patients with acute/chronic cardiotoxicity using anthracyclines, from which perspectives are usually used in clinical evaluation of cardiotoxicity? What measures are taken to balance the survival benefits brought by chemotherapy? At the 15th Oriental Cardiology Conference (OCC 2021) Oncology and Cardiology Forum, Professor Cheng Leilei from Zhongshan Hospital of Fudan University gave professional answers and wonderful sharing on this question and related content.

Professor Cheng Leilei of Zhongshan Hospital Affiliated to Fudan University has various anticancer drugs, which may have acute or chronic cardiovascular side effects, and each has its own characteristics.

For example, for those treated with anthracyclines, more damage may be reflected in cardiac insufficiency after long-term follow-up.

Professor Cheng Leilei pointed out: "Although anthracycline drugs are one of the cornerstone drugs for the treatment of many solid tumors and hematological tumors, it is far from all.

" The current anti-cancer treatment methods are developing rapidly, except for the use of anthracycline drugs.
Representative traditional chemotherapy drugs, there are also some immunotherapy drugs and targeted therapy drugs.

The adverse cardiovascular reactions caused by the latter two drugs may be of more concern to patients.

Anti-cancer treatment causes cardiotoxicity, how does tumor cardiology deal with it? Patients who use various chemotherapy drugs, targeted drugs, immune checkpoint inhibitors and other new anti-cancer drugs may experience blood pressure fluctuations, arrhythmias, and even severe myocarditis within a few days or even a few hours.

Therefore, when cancer patients receive traditional radiotherapy and chemotherapy or anti-cancer treatment with new anti-cancer methods, some cardiovascular adverse reactions may occur.

In the past, patients who had underlying cardiovascular diseases and then discovered malignant tumors at a certain point in time not only need medication, but may also face one or even multiple operations.

Therefore, clinical cardiovascular drugs need to be fully weighed and considered based on this situation.

As far as the emerging discipline of oncology and cardiology is concerned, at this stage, more emphasis is placed on the "three early", that is, early attention, early screening and early diagnosis.

Professor Cheng Leilei said, “I have encountered a patient with coronary heart disease who developed lung cancer six months after implantation of a stent.

This patient developed chest tightness and chest pain during targeted combined immune checkpoint therapy.
At this time, we It is necessary to conduct assessment and analysis to determine whether this situation is caused by fluctuations in coronary heart disease or caused by anti-cancer drugs.

"After a clear diagnosis, a series of methods can be adopted to help patients clarify the condition and provide them with Individualized treatment plan.

"Patient medical treatment is essential to prevent disease".
In medical practice, patient education is an important part of the work of clinical first-line doctors.

Regarding the word "education", Professor Cheng Leilei clarified her point of view: "For an interdisciplinary subject such as oncology and cardiology, "education" may not be limited to the patient or the patient's family.
It is for our colleagues.

For example, although most oncologists have extremely rich experience in the diagnosis and treatment of patient tumors, they may have overlooked cardiovascular protection to some extent.

"Professor Cheng Leilei also mentioned her A popular cardiovascular science book-"Speaking from the Heart 2": "After reading some patients, they have more attention and awareness of their own cardiovascular events; our colleagues in the oncology department also told me In the diagnosis and treatment of patients, there are a few more detailed and thorough diagnosis and treatment ideas.

So I think this matter is very meaningful.

"The general promotion of oncology and cardiology, for the convenience of the people and benefiting the people, tumor cardiology is not only It involves cardiovascular knowledge and basic common sense of some common anti-tumor drugs.
However, the current doctor training system may not pay special attention to these contents.

Therefore, to better develop and popularize oncology cardiology, multi-party collaboration is a preferred way.

At the moment, the multidisciplinary model of diagnosis and treatment (MDT) is the direction of the future development of this discipline.

In April 2018, Zhongshan Hospital Affiliated to Fudan University opened the first multidisciplinary joint clinic for oncology and cardiology in East China.

"Clinical needs, patients have demands, and then we continue to build such a new system.

" Professor Cheng Leilei explained her original intention, "This year, we launched the WeChat online assessment of cardiotoxicity mini program, which is more convenient for the general public.
Cancer patients are evaluated for cardiotoxicity.

According to the guidance of Academician Ge Junbo, we use three colors of red, yellow, and green to indicate the patient's condition-the red light stops, the green light is OK.

"Professor Cheng Leilei said: "With The traffic lights are similar.
When the evaluation result of the mini program is red, we suggest to suspend the existing anti-cancer treatment methods and go to the cardiovascular medicine department to solve the heart problem first.

If it is a green light, let it go all the way.
The patient has palpitations during the treatment.
Premature beats do not affect the overall prognosis.
At this time, we are more inclined to continue the current anti-cancer treatment.

"Now, the mini program is being further promoted.

"We hope to benefit the public through such convenient applications, so that our patients can have a clearer assessment of their own cardiotoxicity.

" Oncological cardiology, preparing for the future, epidemiological statistics, new cancer cases in China in 2020 4.
57 million, accounting for 23.
7% of the world, 8 Chinese people are diagnosed with cancer every minute.

The various side effects of radiotherapy, chemotherapy, immunotherapy, and targeted therapy make the heart overwhelmed.

As a result, a new interdisciplinary oncology and cardiology came into being.

Zhongshan Hospital Affiliated to Fudan University "Three-stage Rocket" Zhongshan Hospital Affiliated to Fudan University launched a "Three-stage Rocket" to promote the rapid development of oncology and cardiology.

The first-level rocket: multidisciplinary joint outpatient clinic for oncology and cardiology.

Zhongshan Hospital affiliated to Fudan University is the first multidisciplinary joint clinic for oncology and cardiology in East China.
It has the four characteristics of "early accurate detection, full cooperation of pharmacists, multiple diseases of patients, and strong specialist foundation".

"Speaking from the Heart 2" second stage rocket: "Concise Clinical Guidance Manual for Oncology Cardiology", "Speaking from the Heart 2", Oriental Cardiology Conference "Oncology Cardiology Forum" and Oncology Cardiology Project Fund Wait.

Among them, the "Concise Clinical Guidance Manual for Oncological Cardiology" is the first actual combat summary in the field of oncological cardiology in my country.
It is both practical and maneuverable.
It focuses on the cardiotoxicity of anti-tumor drugs, namely monitoring, cardiovascular medication and anti-tumor drugs.
The possible conflicts between tumor treatments, cardiovascular management during surgery for tumor patients, and common clinical cardiovascular monitoring methods are introduced.

"Speaking from the Heart 2" brings together Professor Cheng Leilei's clinical research and unique insights on tumor cardiology.
This is also the first popular science book on tumor cardiology in our country.

Cardiotoxicity Assessment Mini Program Level 3 Rocket: Online Cardiotoxicity Assessment Mini Program for Cancer Patients.

Two trial versions, "Online Assessment of Cardiotoxicity for Breast Cancer" and "Online Assessment of Adverse Cardiac Reactions Related to Immune Checkpoint Inhibitors" have been launched.

"Scan the code to test, it only takes one minute"! Convenient operation and online evaluation make it easier for patients to evaluate themselves.

I believe that through the "three-stage rocket" prepared by Professor Cheng Leilei and her team for patients, our patients will have a clearer understanding and assessment of their own conditions and have a better tomorrow.

Expert profile Professor Cheng Leilei, female, doctor of medicine, chief physician of the Department of Cardiac Ultrasound Diagnosis, Zhongshan Hospital, Fudan University, and doctoral supervisor of internal medicine (cardiovascular diseases) at Fudan University.

Take the lead in opening the first multidisciplinary joint clinic for oncology and cardiology in East China.

Good at ultrasound diagnosis of difficult cardiovascular diseases and diagnosis and treatment of cardiology diseases.

Presided over 25 scientific research projects such as the General Program of the National Natural Science Foundation of China and the Shanghai Municipal Health System Excellent Talents Training Program.

Published 89 papers as the first or corresponding author (18 SCI papers).

25 patents were authorized by the State Intellectual Property Office, and 13 patents were successfully transformed.

Won the second prize of Chinese Medical Science and Technology and other awards.

Vice-Chairman of Oncology and Cardiology Committee of Chinese Medical Doctor Association, Standing Committee of Integrated Oncology and Cardiology Branch of Chinese Anti-Cancer Association, Member of Oncology and Cardiology Group of Cardiovascular Branch of Chinese Medical Association, and Anti-tumor of Chinese Society of Clinical Oncology Member of the Special Committee on Drug Safety, Communications Review Expert of the National Natural Science Foundation of China, Communications Review Expert of the Degree Center of the Ministry of Education, and International Editorial Board of "Cardio-Oncology".

Member of Shanghai Writers Association.

Concurrently serves as the deputy secretary-general of the Shanghai Federation of Popular Science Education Bases.

Published cardiovascular science story books "Doctors Know Your Heart Best", "Speaking from the Heart" and my country's first general book on oncology and cardiology "Speaking from the Heart 2", and won the "Top Ten Outstanding Popular Science Works in Healthy China" and other awards.

Deputy Secretary-General of China Medical Equipment Intellectual Property Alliance.

Over the years, he has been responsible for the transformation of more than one hundred medical patents in Fudan and Zhongshan, and published many papers on medical intellectual property management.

From May 27th to 30th, 2021, the 15th Oriental Cardiology Conference (OCC 2021) will be held online and offline simultaneously.

The latest information of the conference is available in one hand! The "Forefront of OCC 2021 Conference" zone is here!